Hu Xin, Fang Yuan, Zheng Jun, He Yazhou, Zan Xin, Lin Sen, Li Xi, Li Hao, You Chao
Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Tumour Biol. 2014 Feb;35(2):903-16. doi: 10.1007/s13277-013-1160-x. Epub 2013 Sep 18.
Epidemiological studies have assessed the association between HIF-1α polymorphisms and cancer risk. However, the results remained conflicting rather than conclusive. Therefore, we performed a systematic review to provide a complete picture and conducted a meta-analysis to derive a precise estimation. We searched PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases until July 2013 to identify eligible studies. Data sets (43) from 39 studies with a total of 10,841 cases and 14,682 controls were included. The most commonly investigated polymorphism was C1772T, followed by G1790A, C111A, and rs2057482. Overall, C1772T and G1790A but not rs2057482 were associated with increased risk for cancer. When stratified by cancer type, C1772T was associated with increased risk for cervical cancer (T/T vs. C/T+C/C: OR = 8.80, 95 % CI = 2.30-33.70), prostate cancer (T vs. C: OR = 1.54, 95 % CI = 1.04-2.30), and other cancers (T vs. C: OR = 1.42, 95 % CI = 1.07-1.89), but not oral, breast, colorectal, endometrial, lung, and bladder cancers or renal cell carcinoma. G1790A was associated with marginal but insignificant risk for prostate cancer (A vs. G: OR = 1.46, 95 % CI = 1.00-2.13, P = 0.056) and with increased risk for oral (A vs. G: OR = 9.66, 95 % CI = 1.31-71.15), lung (A vs. G: OR = 2.27, 95 % CI = 1.74-2.96), and other cancers (A vs. G: OR = 2.06, 95 % CI = 1.26-3.37) and renal cell carcinoma (A/A vs. G/A+G/G: OR = 3.05, 95 % CI = 1.36-6.84), but not breast, colorectal, cervical, or bladder cancer. Furthermore, we detected increased cancer risk in haplotypes TA and CA and in those carrying at least one risk allele, and decreased cancer risk in haplotype TG regarding C1772T and G1790A polymorphisms. Further well-designed studies on various cancer types are warranted to verify our findings.
流行病学研究评估了缺氧诱导因子-1α（HIF-1α）基因多态性与癌症风险之间的关联。然而，结果仍然相互矛盾，而非确凿无疑。因此，我们进行了一项系统综述以呈现全貌，并进行了荟萃分析以得出精确估计。我们检索了PubMed、Embase和中国知网（CNKI）数据库直至2013年7月，以识别符合条件的研究。纳入了来自39项研究的43个数据集，共10841例病例和14682例对照。最常研究的多态性是C1772T，其次是G1790A、C111A和rs2057482。总体而言，C1772T和G1790A与癌症风险增加相关，但rs2057482并非如此。按癌症类型分层时，C1772T与宫颈癌（T/T 对比 C/T+C/C：优势比[OR]=8.80，95%可信区间[CI]=2.30 - 33.70）、前列腺癌（T 对比 C：OR = 1.54，95% CI = 1.04 - 2.30）以及其他癌症（T 对比 C：OR = 1.42，95% CI = 1.07 - 1.89）的风险增加相关，但与口腔癌、乳腺癌、结直肠癌、子宫内膜癌、肺癌、膀胱癌或肾细胞癌无关。G1790A与前列腺癌的边缘性但不显著的风险相关（A 对比 G：OR = 1.46，95% CI = 1.00 - 2.13，P = 0.056），与口腔癌（A 对比 G：OR = 9.66，95% CI = 1.31 - 71.15）、肺癌（A 对比 G：OR = 2.27，95% CI = 1.74 - 2.96）、其他癌症（A 对比 G：OR = 2.06，95% CI = 1.26 - 3.37）以及肾细胞癌（A/A 对比 G/A+G/G：OR = 3.05，95% CI = 1.36 - 6.84）的风险增加相关，但与乳腺癌、结直肠癌、宫颈癌或膀胱癌无关。此外，我们检测到关于C1772T和G1790A多态性，单倍型TA和CA以及携带至少一个风险等位基因的个体癌症风险增加，而单倍型TG的癌症风险降低。有必要针对各种癌症类型开展进一步精心设计的研究以验证我们的发现。
